Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep-Oct;29(5-6):104682.
doi: 10.1016/j.canrad.2025.104682. Epub 2025 Jul 29.

Radiotherapy: Beyond cancer…

Affiliations
Review

Radiotherapy: Beyond cancer…

Nicolas Giraud et al. Cancer Radiother. 2025 Sep-Oct.

Abstract

Radiotherapy, long established as a cornerstone of cancer care, has in recent years broadened its therapeutic reach to include a variety of benign and functional disorders. Advances in imaging, motion management, and highly conformal delivery have made it possible to treat non-malignant conditions with precision and minimal collateral damage. For example, stereotactic arrhythmia radioablation offers a noninvasive, single-session option for refractory ventricular tachycardia, markedly reducing arrhythmic burden and device interventions. In the neuroaxis, stereotactic radiosurgery and hypofractionated regimens achieve durable control of benign intracranial tumours - such as meningiomas, vestibular schwannomas, pituitary adenomas, and craniopharyngiomas - while preserving neurological function. Functional radiosurgery further expands treatment possibilities, targeting lesions to alleviate trigeminal neuralgia and movement disorders without the need for open surgery. Beyond the brain, low-dose radiotherapy leverages anti-inflammatory mechanisms to relieve osteoarticular pain and tendinopathies, orbital irradiation mitigates inflammatory signs in Graves' orbitopathy, and postoperative protocols significantly decrease keloid recurrence. Emerging results from prospective cohorts and multicentre registries demonstrate consistent symptom relief, favourable safety profiles, and notable quality-of-life improvements across these diverse applications. This review synthesizes current clinical practices, technical considerations, and early research findings, and underscores the urgent need for dedicated trials and consensus guidelines. By charting radiotherapy's expanding role in non-cancer settings, we aim to guide multidisciplinary teams and accelerate the development of evidence-based French recommendations.

Keywords: Benign; Bénin; Fonctionnel; Functional; Radiotherapy; Radiothérapie.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interests CO: honoraria for presentation for Brainlab; MA: support for attending meetings and travel from Ipsen; RS: CEO and founder of RT-ABC (benign radiotherapy education company), medical director of Xstrahl Ltd. (radiotherapy machine manufacturer), president of International Organisation for Radiotherapy for Benign Conditions, advisor for Dermacure (US-based benign radiotherapy clinic group), CEO and founder of Reload Clinics Ltd. (tendinopathy clinic in London); CC: personal fees and nonfinancial support from GSK, Merck, Eisai, MSD, AstraZeneca, service as an investigator for clinical trials sponsored by TherAgulX and Roche, support for traveling from Ipsen, Bayer; TL: financial relationships in the form of consultancy contracts, hospitality, or participation in market studies with Accuray Europe, Aquilab, AstraZeneca, Bristol-Myers Squibb, Eisai SAS, Ipsen Pharma, Janssen-Cilag, laboratoires Bouchara-Recordati, M3 Global Research Ltd., Merck Santé, Merck Serono, Pfizer SAS, Pierre Fabre Médicament, public health expertise for association Santélys, member of the Board of Directors of the Société française de radiothérapie oncologique (SFRO) and president of the Association pour la formation continue en oncologie radiothérapie (Afcor); NG, MQ, AC: did not disclose their relationships/activities/interests.

LinkOut - more resources